Tibet Aim Pharm Inc (002826) — Cash Flow-to-Debt Ratio
Tibet Aim Pharm Inc (002826) has a Cash Flow-to-Debt Ratio of 0.34x as of September 2025, meaning its operating cash flow of CN¥87.55 Million could theoretically repay 0% of its total liabilities (CN¥256.63 Million) in one year. See how much free cash does Tibet Aim Pharm Inc generate to measure how efficiently the company converts operating cash flow to free cash.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Tibet Aim Pharm Inc Cash Flow-to-Debt Ratio (2013–2025)
Historical debt coverage capacity for Tibet Aim Pharm Inc across 13 annual periods. Also explore 002826 net assets growth trend to track the company's year-over-year net asset growth rate.
Annual Cash Flow-to-Debt Ratio for Tibet Aim Pharm Inc (2013–2025)
Year-by-year debt coverage analysis for Tibet Aim Pharm Inc. For market capitalisation and broader financial context, see Tibet Aim Pharm Inc market capitalisation.
| Year | CF-to-Debt Ratio | Operating CF (CNY) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | 0.61x | CN¥123.72 Million | CN¥201.65 Million | ▼ -0.5% |
| 2024 | 0.62x | CN¥111.57 Million | CN¥180.89 Million | ▼ -34.3% |
| 2023 | 0.94x | CN¥166.88 Million | CN¥177.68 Million | ▲ +268.0% |
| 2022 | 0.26x | CN¥68.45 Million | CN¥268.21 Million | ▼ -75.7% |
| 2021 | 1.05x | CN¥109.52 Million | CN¥104.36 Million | ▲ +127.9% |
| 2020 | 0.46x | CN¥101.74 Million | CN¥220.94 Million | ▲ +42.5% |
| 2019 | 0.32x | CN¥59.20 Million | CN¥183.24 Million | ▲ +238.6% |
| 2018 | 0.10x | CN¥13.31 Million | CN¥139.53 Million | ▼ -84.1% |
| 2017 | 0.60x | CN¥77.29 Million | CN¥128.76 Million | ▼ -4.6% |
| 2016 | 0.63x | CN¥57.18 Million | CN¥90.93 Million | ▲ +416.5% |
| 2015 | -0.20x | CN¥-29.69 Million | CN¥149.44 Million | ▼ -912.3% |
| 2014 | 0.02x | CN¥2.18 Million | CN¥89.30 Million | ▼ -96.2% |
| 2013 | 0.64x | CN¥52.24 Million | CN¥81.43 Million | — |